8-KShareholder Matters

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (May 6, 2016)

Filed May 6, 2016For Securities:ALNY

Summary

This Form 8-K filing from Alnylam Pharmaceuticals, Inc. (ALNY) on May 6, 2016, details the outcomes of their 2016 Annual Meeting of Stockholders held on May 3, 2016. The primary focus for investors is the overwhelming approval of key governance matters, including the re-election of three Class III directors: Steven M. Paul, M.D., Amy W. Schulman, and Kevin P. Starr. Their re-election indicates continued confidence in the company's leadership and strategic direction. Furthermore, the filing reports strong stockholder support for the compensation of named executive officers through a non-binding advisory vote, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2016. These results suggest a well-aligned shareholder base and robust corporate governance practices at Alnylam Pharmaceuticals.

Key Highlights

  • 1Alnylam Pharmaceuticals held its 2016 Annual Meeting of Stockholders on May 3, 2016.
  • 2Three Class III directors, Steven M. Paul, M.D., Amy W. Schulman, and Kevin P. Starr, were re-elected to serve until the 2019 annual meeting.
  • 3Stockholders provided strong support for the re-election of directors, with substantial 'Votes For' percentages.
  • 4The compensation of the company's named executive officers was approved in a non-binding advisory vote.
  • 5PricewaterhouseCoopers LLP was ratified as the company's independent auditor for the fiscal year ending December 31, 2016, with near-unanimous approval.
  • 685,355,302 shares of common stock were issued and outstanding as of the record date (March 11, 2016).

Frequently Asked Questions

The primary outcomes were the re-election of three Class III directors, the approval of executive compensation in a non-binding advisory vote, and the ratification of the independent auditor, PricewaterhouseCoopers LLP. All key proposals received strong stockholder support.

No, the elections for the three Class III directors were not contested. Steven M. Paul, M.D., Amy W. Schulman, and Kevin P. Starr were all re-elected with a significant majority of votes in favor.

The vote on executive compensation was advisory, meaning it does not legally bind the company. However, strong support for executive compensation typically indicates shareholder satisfaction with management's performance and pay structure. Conversely, a significant 'Votes Against' could signal shareholder concerns.

PricewaterhouseCoopers LLP was ratified by the stockholders as Alnylam's independent auditor for the fiscal year ending December 31, 2016. This ratification received overwhelming approval.